Physician profile
Danielle Goodell
NPI 1841755329
$2,525.00
in general payments reported to CMS, 2019-2025
28 companies · $238 in 2025
The $238 reported for 2025 was more than what a typical Acute Care (Nurse Practitioner) provider received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,372 · 2022: $452 · 2023: $284 · 2024: $179 · 2025: $238.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $701.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $700.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $304.49 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $213.62 | 2021 | |
| Glaxosmithkline, LLC. | $209.01 | 2021-2024 | Trelegy Ellipta |
| Daiichi Sankyo INC. | $185.35 | 2023-2024 | Injectafer, Enhertu |
| Seagen INC. | $159.54 | 2021-2023 | Padcev |
| Amgen INC. | $137.30 | 2021-2023 | Evenity, Prolia |
| Regeneron Healthcare Solutions, INC. | $134.61 | 2021 | |
| Pfizer INC. | $132.01 | 2021-2023 | |
| Merck Sharp & Dohme LLC | $127.40 | 2021-2025 | Keytruda, Lynparza, Welireg |
| Incyte Corporation | $118.73 | 2022-2025 | Zynyz |
| Jazz Pharmaceuticals INC. | $116.64 | 2022 | |
| Octapharma USA, INC. | $107.79 | 2021-2022 | |
| Tempus Ai, INC | $101.14 | 2025 | Xt Cdx |
| Optinose US, INC. | $83.83 | 2021 | |
| Beigene USA, INC. | $50.00 | 2023 | Brukinsa |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $46.97 | 2023 | Reblozyl |
| Genzyme Corporation | $38.49 | 2021-2022 | |
| Janssen Biotech, INC. | $36.54 | 2022 | |
| Rigel Pharmaceuticals, INC. | $36.22 | 2023 | Tavalisse, Rezlidhia |
| Teva Pharmaceuticals USA, INC. | $34.78 | 2021 | |
| Csl Behring | $24.54 | 2021 | |
| Adaptive Biotechnologies Corporation | $23.92 | 2023 | Clonoseq |
| Kaleo, INC. | $23.18 | 2021 | |
| Celgene Corporation | $19.31 | 2022 | |
| Horizon Therapeutics Plc | $15.33 | 2021 | |
| Geron Corporation | $15.30 | 2025 | Rytelo |
| Pharming Healthcare, INC. | $15.07 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.89 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Goodell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.